Akers Biosciences Signs Distribution Agreement for BreathScan OxiChek(TM)

THOROFARE, NJ--(Marketwired - Jun 27, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM:AKR) (the "Company" or "Akers Bio"), a developer of rapid health information technologies, has signed its first distribution agreement for BreathScan OxiChek™ ("OxiChek") with Aero-Med, a division of Cardinal Health, a Fortune 500 health care services organization.

Developed by Akers Bio as part of the Akers Wellness line, OxiChek is the first disposable breath test to rapidly determine levels of oxidative stress in the body by measuring the levels of certain abundant free radicals. Frequent use of OxiChek may help health practitioners to monitor and adjust their clients' regimen of nutritional supplementation in order to manage oxidative stress -- an indicator of the overall health and wellbeing of a person. OxiChek works with BreathScan Lync™, the new Bluetooth-enabled reading device from Akers Wellness, to enable users to monitor oxidative stress via a mobile device.

Published: 27 June 2016

Written by Editor

Nymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without Cancer

Study Shows Major Reduction to Cumulative Incidence of Prostate Cancer in Study to 1.3%

HASBROUCK HEIGHTS, N.J., June 22, 2016 -- Nymox Pharmaceutical Corporation (NYMX) announced today results from the Company's 7 year prospective placebo controlled double blind studies of treatment of 995 U.S. men with the Company's lead drug fexapotide. Men who received fexapotide showed a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease.

The men in the study received fexapotide or placebo for the treatment of their prostate enlargement (BPH) symptoms. All men were thoroughly evaluated to exclude any prostate cancer prior to qualifying for enrollment in the studies. The participants were enrolled at over 70 top well-known U.S. urological investigational centers, and were followed for up to 7 years (median of 5 years) after treatment.

Published: 22 June 2016

Written by Editor

Nasdaq Up on News Project Update

Exact Sciences Statement Regarding Pending USPSTF Colorectal Cancer Screening Guidelines

MADISON, Wis., June 15, 2016 -- Exact Sciences (Nasdaq: EXAS) issued the following statement today: "We are aware that the U.S. Preventive Services Task Force's final colorectal cancer screening guidelines are anticipated to be issued in the near future. Exact Sciences will comment on the guidelines once they are released by the task force or published in the Journal of the American Medical Association."

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. For more information, please follow us on Twitter @ExactSciences or find us on Facebook.

Published: 15 June 2016

Written by Editor

Nasdaq Up on News Project Update

Great Basin Attends ASM Microbe 2016 to Transform the Way Hospitals Diagnose Infectious Disease

Three Featured Posters Validate the Company’s Newly-Cleared Staph ID/R Blood Culture Panel and Shiga Toxin Direct Molecular Assays

SALT LAKE CITY--- Great Basin Scientific, Inc. (GBSN), a molecular diagnostics company, announced today it is bringing its innovative solution to ASM Microbe 2016 in Boston, Mass., June 17-20 to help small to medium-sized hospitals learn more about the company's cost-effective, sample-to-result platform to reduce costs, increase efficiency and provide better patient outcomes. ASM Microbe 2016—integrating the American Society for Microbiology’s two premier events, the General Meeting and ICAAC—showcases the best microbial sciences in the world and provides a one-of-a-kind forum to explore the complete spectrum of microbiology, from basic science to translation and application. Great Basin will be exhibiting in booth 219, where ASM attendees can receive one-on-one demonstrations of the platform and schedule meetings with Product and Sales team leaders.

Published: 09 June 2016

Written by Editor

Nasdaq Up on News

Luminex Corporation and Nanosphere, Inc. Provide Update on Acquisition Agreement

AUSTIN, Texas and NORTHBROOK, Ill., May 23, 2016 -- Luminex Corporation (LMNX) and Nanosphere, Inc. (NSPH) announced today that they have entered into an amendment to the definitive agreement under which Luminex will acquire Nanosphere, a leader in the molecular microbiology and molecular diagnostic market. The purchase price has been increased to $1.70 per share from $1.35 per share in an all cash transaction valued at approximately $77 million. This increase was in response to an unsolicited third party offer for Nanosphere at $1.50 per share.

Published: 23 May 2016

Written by Editor

Nasdaq M & A Up on News

Akers Biosciences Inc ( AKER )

Akers Biosciences Signs Distribution Agreement for BreathScan OxiChek(TM)

Nymox Pharmaceutical Corporation ( NYMX )

Nymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without Cancer

Exact Sciences ( EXAS )

Exact Sciences Statement Regarding Pending USPSTF Colorectal Cancer Screening Guidelines

Great Basin Scientific Inc ( GBSN )

Great Basin Attends ASM Microbe 2016 to Transform the Way Hospitals Diagnose Infectious Disease

Nanosphere Inc ( NSPH )

Luminex Corporation and Nanosphere, Inc. Provide Update on Acquisition Agreement